Document is current
Any future updates will be listed below
-
Authors
Broadwell, Aaron
Schechtman, Joy
Conaway, Douglas
Kivitz, Alan
Shiff, Natalie J.
Black, Shawn
Xu, Stephen
Langholff, Wayne
Schwartzman, Sergio
Curtis, Jeffrey R.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02728934 at ClinicalTrials.govDocuments that mention this clinical trial
Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
https://doi.org/10.1007/s40744-021-00354-4
Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study
https://doi.org/10.1186/s41927-023-00329-8
Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
https://doi.org/10.1007/s40744-023-00533-5
-
Funding
Funding for this research was provided by:
Janssen Scientific Affairs, LLC, Horsham, PA, USA
- License Information
-
More Information
Article History
Received: 23 May 2022
Accepted: 7 March 2023
First Online: 27 March 2023
Declarations
:
: This study was conducted according to the Declaration of Helsinki and the International Committee on Harmonisation good clinical practices. The study protocol was reviewed by a centralized institutional review board (Copernicus Group, Approval QUI1-15-645); ethics committee review was not performed as there were no study sites outside the US. All patients provided written informed consent.
: Not applicable.
: AB received consulting fees from Abbvie, Amgen, Aurinia, Celgene, Eli Lilly and Company, Janssen, Novartis, Pfizer, and Sandoz and speaker fees from Amgen, Abbvie, Eli Lilly and Company, Horizon, Janssen, Mallinckrodt, Novartis, Pfizer, Radius, Sanofi/Regeneron, and UCB. JS received speaker fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, ChemoCentryx, Eli Lilly and Company, Novartis, Mallinckrodt, Pfizer, Radius, Scipher, and UCB; and is on the scientific advisory board of Janssen. DC received consulting fees from Janssen and speaking fees from Janssen and Amgen. AK received stock options or bond holdings in a for-profit corporation or self-directed pension plan from Amgen, Gilead Sciences, Novartis, Pfizer, and Sanofi; received research grants from Janssen Research and Development; is an owner or partner for Amgen, Gilead Sciences, Inc, Novartis, Pfizer, and Sanofi; received consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Flexion, Genzyme, Gilead Sciences, Janssen, Pfizer, Sanofi, SUN Pharma Advanced Research, and UCB; and speaker fees from AbbVie, Celgene, Eli Lilly and Company, Flexion, Genzyme, Horizon, Merck, Novartis, Pfizer, and Sanofi. SS received speaker fees from AbbVie, Eli Lilly and Company, Janssen, Novartis, Pfizer, Regeneron, Sanofi, and UCB and consultant fees from AbbVie, Eli Lilly and Company, Gilead, Janssen, Myriad, Novartis, Regeneron, Samsung, Sanofi, and UCB; owns stock in Amgen, Boston Scientific, Gilead, Medtronic, and Pfizer; and is a board member of National Psoriasis Foundation, and on the scientific advisory boards of Jubilant, Myriad, and Stelexis. JRC received grant/research support from AbbVie, Amgen, Bristol-Myers Squibb, CorEvitas, Eli Lilly and Company, Janssen, Myriad, Novartis, Pfizer, Sanofi, and UCB and consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, CorEvitas, Eli Lilly and Company, Janssen, Myriad, Novartis, Pfizer, Sanofi, and UCB. NJS is an employee of Janssen Scientific Affairs, LLC, a wholly owned subsidiary of Johnson and Johnson, and owns stock in AbbVie, Gilead, Iovance, Jazz Pharmaceuticals, Johnson and Johnson, Novavax, and Viatris. SB, SX, and WL are employees of Janssen Research and Development, LLC, a wholly owned subsidiary of Johnson and Johnson, and own stock in Johnson and Johnson.
